[Mesenchymal stromal cells in the treatment of graft-versus-host disease: where do we stand?]. / Mesenchymale Stromazellen bei der Therapie der Graft-versus-Host-Erkrankung: Wo stehen wir?

ABSTRACT

Medicinal products based on mesenchymal stromal cells (MSC) are expected to have a therapeutic benefit in a variety of conditions and, accordingly, are being tested in many clinical studies. The treatment and prevention of graft-versus-host disease (GVHD) is one of the world's most widely studied MSC therapy concepts. So far, one MSC medicinal product has been approved for the treatment of GvHD. This article gives an overview of the particular features related to the production of MSC-based medicinal products, the state of non-clinical research, and the clinical development status of MSCs and the associated challenges, especially in the context of GvHD.